查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530899

HIV 药物市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034 年

HIV Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 153 Pages | 商品交期: 2-10个工作天内

价格

HIV 药物市场 - 报告范围

TMR 关于全球 HIV 药物市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。 ，考虑2024年为基准年，2034年为预测年。报告中也提供了2024年至2034年全球爱滋病药物市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解爱滋病毒药物市场。

市场概况
2023年市场价值 286 亿美元
2034 年市场价值 475 亿美元
复合年增长率 4.7%

该报告深入探讨了全球爱滋病毒药物市场的竞争格局。全球爱滋病毒药物市场的主要参与者已经确定，并且每个参与者都根据不同的属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球 HIV 药物市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：按药物类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药物类型，2020-2034
    • 核苷逆转录酶抑制剂 (NRTI)
    • 非核苷逆转录酶抑制剂 (NNRTI)
    • 蛋白酶抑制剂 (PI)
    • 融合抑制剂 (FI)
    • CC 趋化因子受体 5 型 (CCR5)
    • 整合酶抑制剂
    • 附着抑制剂
    • 附着后抑制剂
    • 药物动力学增强剂
    • 暴露后预防 (PEP)
    • 暴露前预防 (PrEP)
    • 其他（爱滋病毒联合用药等）
  • 市场吸引力分析：按药品类型

第 7 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院药房
    • 零售药局
    • 网路药局
  • 市场吸引力分析：按配销通路

第 8 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 9 章：北美市场分析与预测

第 10 章：欧洲市场分析与预测

第 11 章：亚太市场分析与预测

第 12 章：拉丁美洲市场分析与预测

第 13 章：中东和非洲市场分析与预测

第 14 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • GSK plc
    • AbbVie Inc.
    • Cipla Limited
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
Product Code: TMRGL86226

HIV Drugs Market - Scope of Report

TMR's report on the global HIV drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global HIV drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HIV drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the HIV drugs market.

Market Snapshot
Market Value in 2023US$ 28.6 Bn
Market Value in 2034US$ 47.5 Bn
CAGR4.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HIV drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HIV drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HIV drugs market.

The report delves into the competitive landscape of the global HIV drugs market. Key players operating in the global HIV drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HIV drugs market profiled in this report.

Key Questions Answered in Global HIV drugs Market Report:

  • What is the sales/revenue generated by HIV drugs across all regions during the forecast period?
  • What are the opportunities in the global HIV drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

HIV Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global HIV drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global HIV drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HIV drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HIV Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global HIV Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global HIV Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2020-2034
    • 6.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 6.3.3. Protease Inhibitors (PIs)
    • 6.3.4. Fusion Inhibitors (FIs)
    • 6.3.5. C-C Chemokine Receptor Type 5 (CCR5)
    • 6.3.6. Integrase Inhibitors
    • 6.3.7. Attachment Inhibitors
    • 6.3.8. Post Attachment Inhibitors
    • 6.3.9. Pharmacokinetic Enhancers
    • 6.3.10. Post-Exposure Prophylaxis (PEP)
    • 6.3.11. Pre-Exposure Prophylaxis (PrEP)
    • 6.3.12. Others (Combination HIV Medications, etc.)
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global HIV Drugs Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global HIV Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2020-2034
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America HIV Drugs Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Drug Type, 2020-2034
    • 9.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 9.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 9.3.3. Protease Inhibitors (PIs)
    • 9.3.4. Fusion Inhibitors (FIs)
    • 9.3.5. C-C Chemokine Receptor Type 5 (CCR5)
    • 9.3.6. Integrase Inhibitors
    • 9.3.7. Attachment Inhibitors
    • 9.3.8. Post Attachment Inhibitors
    • 9.3.9. Pharmacokinetic Enhancers
    • 9.3.10. Post-Exposure Prophylaxis (PEP)
    • 9.3.11. Pre-Exposure Prophylaxis (PrEP)
    • 9.3.12. Others (Combination HIV Medications, etc.)
  • 9.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Value Forecast, by Country, 2020-2034
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Drug Type
    • 9.6.2. By Distribution Channel
    • 9.6.3. By Country

10. Europe HIV Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Type, 2020-2034
    • 10.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 10.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 10.3.3. Protease Inhibitors (PIs)
    • 10.3.4. Fusion Inhibitors (FIs)
    • 10.3.5. C-C Chemokine Receptor Type 5 (CCR5)
    • 10.3.6. Integrase Inhibitors
    • 10.3.7. Attachment Inhibitors
    • 10.3.8. Post Attachment Inhibitors
    • 10.3.9. Pharmacokinetic Enhancers
    • 10.3.10. Post-Exposure Prophylaxis (PEP)
    • 10.3.11. Pre-Exposure Prophylaxis (PrEP)
    • 10.3.12. Others (Combination HIV Medications, etc.)
  • 10.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Distribution Channel
    • 10.6.3. By Country/Sub-region

11. Asia Pacific HIV Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Type, 2020-2034
    • 11.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 11.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 11.3.3. Protease Inhibitors (PIs)
    • 11.3.4. Fusion Inhibitors (FIs)
    • 11.3.5. C-C Chemokine Receptor Type 5 (CCR5)
    • 11.3.6. Integrase Inhibitors
    • 11.3.7. Attachment Inhibitors
    • 11.3.8. Post Attachment Inhibitors
    • 11.3.9. Pharmacokinetic Enhancers
    • 11.3.10. Post-Exposure Prophylaxis (PEP)
    • 11.3.11. Pre-Exposure Prophylaxis (PrEP)
    • 11.3.12. Others (Combination HIV Medications, etc.)
  • 11.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Distribution Channel
    • 11.6.3. By Country/Sub-region

12. Latin America HIV Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Type, 2020-2034
    • 12.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 12.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 12.3.3. Protease Inhibitors (PIs)
    • 12.3.4. Fusion Inhibitors (FIs)
    • 12.3.5. C-C Chemokine Receptor Type 5 (CCR5)
    • 12.3.6. Integrase Inhibitors
    • 12.3.7. Attachment Inhibitors
    • 12.3.8. Post Attachment Inhibitors
    • 12.3.9. Pharmacokinetic Enhancers
    • 12.3.10. Post-Exposure Prophylaxis (PEP)
    • 12.3.11. Pre-Exposure Prophylaxis (PrEP)
    • 12.3.12. Others (Combination HIV Medications, etc.)
  • 12.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Distribution Channel
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa HIV Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Type, 2020-2034
    • 13.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 13.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 13.3.3. Protease Inhibitors (PIs)
    • 13.3.4. Fusion Inhibitors (FIs)
    • 13.3.5. C-C Chemokine Receptor Type 5 (CCR5)
    • 13.3.6. Integrase Inhibitors
    • 13.3.7. Attachment Inhibitors
    • 13.3.8. Post Attachment Inhibitors
    • 13.3.9. Pharmacokinetic Enhancers
    • 13.3.10. Post-Exposure Prophylaxis (PEP)
    • 13.3.11. Pre-Exposure Prophylaxis (PrEP)
    • 13.3.12. Others (Combination HIV Medications, etc.)
  • 13.4. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Distribution Channel
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2023)
  • 14.3. Company Profiles
    • 14.3.1. Teva Pharmaceutical Industries Ltd.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Boehringer Ingelheim International GmbH
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Johnson & Johnson
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. F. Hoffmann-La Roche Ltd.
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Gilead Sciences, Inc.
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. GSK plc
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. AbbVie Inc.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Cipla Limited
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Bristol-Myers Squibb Company
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Merck & Co., Inc.
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 02: Global HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 03: Global HIV Drugs Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 04: North America HIV Drugs Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 05: North America HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 06: North America HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 07: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 08: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 09: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 10: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 11: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 12: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 15: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 18: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global HIV Drugs Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global HIV Drugs Market Revenue (US$ Bn), by Drug Type, 2023
  • Figure 03: Global HIV Drugs Market Value Share, by Drug Type, 2023
  • Figure 04: Global HIV Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 05: Global HIV Drugs Market Value Share, by Distribution Channel, 2023
  • Figure 06: Global HIV Drugs Market Value Share, by Region, 2023
  • Figure 07: Global HIV Drugs Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 08: Global HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 09: Global HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
  • Figure 10: Global HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 11: Global HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
  • Figure 12: Global HIV Drugs Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 13: Global HIV Drugs Market Attractiveness Analysis, by Region, 2020-2034
  • Figure 14: North America HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 15: North America HIV Drugs Market Attractiveness Analysis, by Country, 2020-2034
  • Figure 16: North America HIV Drugs Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 17: North America HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 18: North America HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 19: North America HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
  • Figure 20: North America HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
  • Figure 21: Europe HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 22: Europe HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 23: Europe HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 24: Europe HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 25: Europe HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 26: Europe HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
  • Figure 27: Europe HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
  • Figure 28: Asia Pacific HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 29: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 30: Asia Pacific HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 31: Asia Pacific HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 32: Asia Pacific HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
  • Figure 34: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
  • Figure 35: Latin America HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 36: Latin America HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 37: Latin America HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 38: Latin America HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 39: Latin America HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Latin America HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
  • Figure 41: Latin America HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
  • Figure 42: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 43: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
  • Figure 44: Middle East & Africa HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 45: Middle East & Africa HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 46: Middle East & Africa HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 47: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
  • Figure 48: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034